Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL-82
- Development stage
- Phase 2
- Lead developer
- Zenitar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZL-82 is an orally bioavailable small molecule inhibitor of Janus kinase 3 (JAK3), developed by Chengdu Zenitar Biomedical Technology. It functions as a highly selective, covalent, and irreversible inhibitor, specifically targeting the JAK3 isoform while demonstrating minimal activity against JAK1, JAK2, and TYK2. This high selectivity is intended to provide a wider therapeutic window and improved safety profile compared to first-generation, non-selective JAK inhibitors. ZL-82 is currently being evaluated in clinical trials for the treatment of moderate to severe atopic dermatitis and has shown potential for the treatment of rheumatoid arthritis.
- Other names
- zl-82zl82zl 82
02
Targets
Beyond the preview
Go deeper on ZL-82.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL-82.